Eli Lilly has become the leading commercial platform in the rapidly expanding obesity and cardiometabolic market. Growth, strategic execution, and near-term investor expectations are increasingly concentrated in the tirzepatide franchise—Mounjaro for diabetes and Zepbound for obesity—while Foundayo (orforglipron) and retatrutide extend the product cycle. Lilly’s broader portfolio spans diabetes, obesity, oncology, immunology, and neuroscience, with Ebglyss, Jaypirca, and Omvoh providing diversification beyond the two flagship incretin brands 27,32. Yet the central conclusion is clear: GLP-1-led obesity demand has transformed Lilly’s scale and earnings profile while exposing the company to payer policy, manufacturing requirements, intensifying competition, litigation, counterfeit and compounded products, and eventual generic erosion.
The evidence base is concentrated and recent, with most claims published between 5 and 17 August 2026, supplemented by earlier April–May reporting on first-quarter sales and capacity. The strongest foundation comes from higher-corroboration claims: Lilly held 60.1% of the U.S. obesity and diabetes drug market in the first quarter based on four sources 22; Zepbound’s sales growth and commercial trajectory are supported by as many as eight sources 2,8,15,21,26,32; and the company’s leadership in obesity is broadly corroborated by an approximately 60% prescription share, including roughly 70% of injectable prescriptions 33.
Tirzepatide Is the Earnings Anchor
The active pharmaceutical ingredient of Lilly’s current growth is tirzepatide. The molecule is sold as Mounjaro for type 2 diabetes and, in the United States, as Zepbound for chronic weight management and obstructive sleep apnea; outside the United States, Mounjaro is also marketed for obesity 7,8,17,19,26. This brand architecture gives Lilly exposure to two large, overlapping disease markets while preserving a distinct commercial identity for each indication.
Mounjaro and Zepbound are repeatedly identified as the company’s primary growth drivers 15,19,21,31,32,33,35. Their combined 2025 revenue exceeded $36 billion 18, and the products generated $14.9 billion in combined sales in the second quarter of 2026 33. U.S. product volume rose 37% during the quarter, primarily because of Mounjaro and Zepbound 22.
Zepbound’s Commercial Scale
Zepbound is Lilly’s most visible obesity asset. It is an FDA-approved prescription treatment based on tirzepatide, a dual GLP-1/GIP agonist, for chronic weight management and obstructive sleep apnea 1,20,24,27,31. Reported quarterly revenue figures are consistently in the range of $4–5 billion, although the exact amounts vary by period and source. Revenue grew 83% year over year, from $2.3 billion in the first quarter of 2025 to $4.2 billion in the first quarter of 2026 2,8,15,21,26,32; other reporting describes 79% growth to $4.1 billion 3,22,24. Second-quarter U.S. revenue was approximately $4.9 billion, with a further $0.1 billion generated outside the United States 5.
For the six months ended June 30, 2026, reported Zepbound revenue was $9.088 billion, including $9.006 billion in the United States and only $81 million internationally 34. The 99% U.S. contribution in the second quarter 7, together with the earlier observation that nearly all first-quarter revenue was domestic 7, makes international expansion a substantial opportunity. It also underscores the franchise’s current geographic concentration.
The demand signal is unusually strong. Lilly’s U.S. obesity prescriptions increased 78% year over year 33, and the company’s medicines represented approximately six out of ten U.S. obesity prescriptions 33. Demand for Mounjaro and Zepbound has been described as surging or even “runaway” 4,22,35. Management’s guidance increase was attributed to continued demand for both drugs 31, while Zepbound was specifically cited as a driver of the full-year outlook and domestic demand was characterized as durable 4,28,31. The same demand supported second-quarter revenue growth and the broader earnings narrative 4,10,26,33,35.
Zepbound’s clinical profile remains commercially relevant. One Phase 3 study reported mean weight loss of 20.2% 37, while a separate trial cited mean weight loss of 15.8% at 68 weeks 6. These figures should not be treated as directly comparable without adjusting for trial context.
Access and Manufacturing: The Necessary Excipients
Coverage expansion could materially broaden the addressable market. The Medicare GLP-1 Bridge Program expanded coverage for Lilly’s obesity medicines 33, reportedly reaching 20 million eligible Americans and increasing U.S. coverage by 35% 33. The program includes Zepbound, Foundayo, and Novo Nordisk’s Wegovy 26. As of 10 August, Amazon Pharmacy offered Zepbound to Medicare patients for a fixed $50 monthly copayment 25. These agreements formed part of Lilly’s U.S. government pricing arrangements, while the company continues discussions with CMS regarding longer-term Medicare access 34. State Medicaid programs may also expand access, although uptake remains unknown 34.
The principal caveat is duration: the Bridge Program is scheduled to end on 31 December 2027 26. Coverage is therefore a meaningful near-term volume catalyst, but not yet a fully established long-term reimbursement base. Lilly’s demand remains dependent on payer and coverage policy 22.
Manufacturing capacity is the physical constraint on converting prescription demand into revenue. Lilly previously faced manufacturing limitations that restricted its ability to serve Zepbound and Mounjaro demand 4, and the company has expanded capacity in response to supply pressure 4. New manufacturing capacity is being brought online for the obesity and diabetes franchises 15. This investment should allow Lilly to monetize prescription growth and support international expansion, but it also introduces execution risk: capacity additions, quality compliance, and distribution must progress in balance. Approved therapies remained available while some patients continued to use cheaper compounded products 17, indicating that affordability—not supply alone—remains a leakage point.
Lifecycle Extension: Foundayo and Retatrutide
Foundayo provides Lilly with a second growth vector and a response to the convenience advantage of oral therapy. Orforglipron is an oral GLP-1 receptor agonist marketed as Foundayo 15,16,17,27. Lilly launched it in the United States for obesity in the second quarter of 2026 21,34. The product generated $98 million in second-quarter sales 21, and approximately one-quarter of new oral-obesity patients reportedly began treatment with Foundayo 22.
Lilly characterizes the oral market as expansionary rather than cannibalistic to Zepbound demand 22. If that view proves correct, oral therapy could enlarge total treatment adoption by reaching patients unwilling or unable to use injections. Lilly has submitted Foundayo for type 2 diabetes approval in the United States, European Union, and Japan 34, completed its U.S. regulatory submission with action expected later in 2026 33, and submitted orforglipron across major international markets while launching Mounjaro internationally 34.
The early commercial position is not unambiguously strong. Foundayo has been described as falling short of expectations 9, while Novo Nordisk’s oral Wegovy reached the market approximately three months earlier 15,21. Foundayo therefore enters an oral market in which Wegovy is already established and competition is intensifying 15,16. The United Kingdom’s MHRA authorized orforglipron for weight management and type 2 diabetes 11,13,16, but NHS access remains contingent on a future NICE decision 13. The UK approval strengthens Lilly’s international positioning and its effort to capture oral-market share from Novo Nordisk 16, but regulatory approval should not be equated with reimbursed uptake.
Retatrutide is Lilly’s next major pipeline option. It is a late-stage, next-generation obesity asset and a triple agonist 15,26. Phase 3 trials have recently been completed, with strong weight-loss results reported 15,27,32. Lilly says a complete clinical data package is available to support global regulatory registration 15,33, and CEO David Ricks has framed Phase 3 retatrutide development as part of the company’s next-generation obesity strategy 26. Early data suggest potentially greater weight loss than Zepbound, although that comparison remains unconfirmed 20. Retatrutide supports the durability of Lilly’s obesity franchise beyond tirzepatide, but its development, regulatory, and commercial outcomes remain uncertain.
Competition and Market Structure
The scale of the opportunity has attracted a broad competitive field. Novo Nordisk and Lilly currently dominate the market 38, competing through injectable and oral products 21, with Wegovy serving as Novo’s principal obesity competitor 17,19. Competition between the two companies is intensifying 16,36. Other potential entrants—including Amgen, Roche, Pfizer, Viking Therapeutics, Structure Therapeutics, Boehringer Ingelheim, and Zealand Pharma—are advancing GLP-1 or related candidates 18.
Lilly’s current share leadership and an estimated revenue share of approximately 60% 27 are meaningful advantages, but they are not permanent barriers to entry. Stable supply reported by both Lilly and Novo 17 may reduce availability-driven differentiation and shift competition toward efficacy, tolerability, price, access, adherence, and brand execution. The alchemy of market dominance will therefore depend not only on the molecule, but also on formulation differentiation, manufacturing yield, supply-chain integrity, and pharmacoeconomics.
Legal, Regulatory, and Product-Integrity Risks
Legal and regulatory risks are becoming more material as the market scales. Lilly sued six U.S. entities on 13 August over alleged illegal sales of experimental retatrutide 25 and is pursuing broader enforcement against illicit distribution 12,17,29. The company has identified social media and e-commerce platforms as enablers of the illegal market and says its actions are intended to protect patient safety 17,29. These efforts support the integrity of the pipeline and reduce risks from unapproved products, but the need for enforcement underscores the difficulty of controlling a high-demand category.
Separately, plaintiffs have filed lawsuits since August 2023 alleging injuries associated with incretin medicines, including Mounjaro, Trulicity, and Zepbound 34. Novo Nordisk filed a federal lawsuit on 21 July alleging that Lilly used outdated clinical comparisons in advertising for Zepbound and Mounjaro. Lilly denies wrongdoing and maintains the validity of its SURMOUNT-5 data 27. These disputes create potential injunction, reputational, and marketing risks, although the claims do not establish liability.
Generic manufacturers have also filed ANDAs seeking approval for generic Mounjaro and/or Zepbound before some or all Orange Book patents expire 34. Intellectual-property durability is consequently an important long-term monitoring item. As the market matures, counterfeit activity, compounding, advertising disputes, product-liability claims, and generic challenges become impurities in an otherwise exceptionally powerful growth formulation.
Investment Implications
Lilly has evolved from a diversified pharmaceutical company into a high-growth cardiometabolic leader whose valuation and earnings narrative are increasingly sensitive to incretin execution. Mounjaro and Zepbound accounted for 65% of revenue in the six months ended June 30, 2026, while another estimate places their contribution at 56% of total company revenue 9,34. Although the exact share differs by measurement period and denominator, both figures demonstrate concentration risk. The same products provide exceptional growth and operating scale 23,32, but any deceleration in prescription growth, pressure on net pricing, adverse safety developments, reimbursement tightening, or manufacturing disruption would have an outsized effect on the company.
The strategic offset is a layered lifecycle model: maximize tirzepatide through additional indications and geographies; add an oral product to widen access; advance retatrutide as a potentially more potent successor; and use manufacturing investment to remove supply constraints. Lilly’s leadership in diabetes and obesity 30,32,35 and its deep incretin pipeline 28 provide a stronger platform than a single-brand thesis. The oral market could be additive rather than cannibalistic if Foundayo reaches patients who do not initiate injectable treatment, while retatrutide could defend Lilly’s efficacy position in the next product cycle. Nevertheless, Foundayo’s modest initial sales, first-mover disadvantage versus oral Wegovy, and uncertain reimbursement show why pipeline optionality should not yet be valued as equivalent to tirzepatide cash flow.
Investors should distinguish robust current facts from lower-confidence forward claims. The strongest facts are Lilly’s market share, the scale of tirzepatide revenue, strong demand, prescription growth, and Zepbound’s overwhelmingly U.S.-based sales 2,5,7,8,15,21,22,26,32,33,34. More tentative are the ultimate size of international markets 26, retatrutide’s superiority to Zepbound 20, the durability of Medicare access after 2027 26, the uptake of state Medicaid expansion 34, and Foundayo’s eventual commercial contribution. Reported Zepbound revenue also ranges from $4.1 billion to $4.93 billion depending on quarter, geography, and source 3,7,8,14,22,24; these figures should not be combined mechanically. In addition, claims describing Zepbound as a GLP-1 receptor “antagonist” 20 conflict with the broader descriptions of it as a GLP-1/GIP dual agonist 20. The latter formulation is more internally consistent.
The actionable conclusion is a barbell view of Lilly. Near-term fundamentals remain supported by volume, coverage expansion, capacity additions, and strong tirzepatide demand. Medium- and long-term returns, however, depend on converting Foundayo and retatrutide into successful lifecycle extensions without losing share to Novo Nordisk or emerging entrants. Monitoring should focus on U.S. net pricing and Medicare utilization, Foundayo’s prescription ramp and international reimbursement, retatrutide Phase 3 and regulatory milestones, capacity utilization, litigation outcomes, counterfeit activity, and the timing or scope of generic entry.
Key Takeaways
- Tirzepatide is the earnings anchor. Mounjaro and Zepbound drive the majority of recent growth, with second-quarter combined sales of $14.9 billion and six-month revenue concentration of roughly 56–65%, depending on the measure 9,33,34.
- Access and capacity are the immediate catalysts. Medicare’s $50 Bridge Program, strong prescription growth, and new manufacturing capacity can expand volume, but the program’s 2027 expiry and continuing payer-policy dependence limit visibility 22,26,33.
- The pipeline supports franchise durability but carries execution risk. Foundayo broadens Lilly into oral therapy, while retatrutide offers next-generation potential. Both face competition, with Foundayo trailing oral Wegovy in timing and early sales 15,21.
- Risk is rising with market maturity. Novo Nordisk and multiple pipeline entrants, advertising and product-liability litigation, illicit retatrutide sales, and generic ANDAs could pressure Lilly’s market share, margins, and long-term exclusivity 16,18,25,27,34.
Lilly is therefore best understood as a market-leading but increasingly concentrated and contested obesity platform—not an uncomplicated growth story. The scientific foundation is strong, the manufacturing opportunity is substantial, and the business model is scaling rapidly. Quality cannot be rushed, however: durable shareholder value will depend on whether clinical efficacy, manufacturing capability, payer access, and legal durability crystallize together.